November 8, 2005
ChemGenex To Present At Rodman & Renshaw Techvest 7th Annual Healthcare Conference
MELBOURNE, Australia, and MENLO PARK, California U.S.A. (November 8, 2005): ChemGenex Pharmaceuticals...
October 11, 2005
Forbes Profiles ChemGenex's Inflammation Discovery
MELBOURNE, Australia, and MENLO PARK, California U.S.A (October 11, 2005): ChemGenex Pharmaceuticals...
October 10, 2005
ChemGenex Team Pinpoints Inflammation Gene
MELBOURNE, Australia, and MENLO PARK, California U.S.A (October 10, 2005): ChemGenex Pharmaceuticals...
October 5, 2005
ChemGenex Initiates New Phase 2 Trial of Ceflatonin® in Gleevec® Resistant CML
MELBOURNE, Australia, and MENLO PARK, California U.S.A (October 5, 2005): ChemGenex Pharmaceuticals...
September 27, 2005
ChemGenex Personalized Medicine Clinical Trial Expanded to Patients with Breast and Ovarian Cancers
MELBOURNE, Australia, and MENLO PARK, California U.S.A (September 27, 2005): ChemGenex Pharmaceuticals...
September 26, 2005
RETURN OF CAPITAL
The Charter Pacific Board today announced their intention to recommend a return of capital of five cents...
September 9, 2005
Charter Pacific's solid profit continues strong returns on shareholder funds
Listed Investment Company Charter Pacific Corporation (ASX:CHF) today posted a gross profit of $15.1...
August 30, 2005
2004-05 Financial Report Highlights Successful Year For ChemGenex
MELBOURNE, Australia, and MENLO PARK, California U.S.A. (August 30, 2005): ChemGenex Pharmaceuticals...
August 4, 2005
ChemGenex Joins New NASDAQ Health Care Index
MELBOURNE, Australia and MENLO PARK, California U.S.A (August 4, 2005): ChemGenex Pharmaceuticals...
July 28, 2005
ChemGenex Appoints Two Experienced Directors To Board
MELBOURNE, Australia, and MENLO PARK, California U.S.A. (July 28, 2005): ChemGenex Pharmaceuticals Limited...
July 27, 2005
Australian Research Council Supports Two New Obesity & Type 2 Diabetes Studies by ChemGenex Pharmaceuticals' Researchers
MELBOURNE, Australia, and MENLO PARK, California U.S.A. (July 27, 2005): The pre-eminent position of...
July 18, 2005
ChemGenex Announces Strategy for Registration-Directed Clinical Trials for Ceflatonin®
MELBOURNE, Australia, and MENLO PARK, California U.S.A. (July 18, 2005): ChemGenex Pharmaceuticals Limited...
June 28, 2005
Updated ChemGenex Overview Presentation
MELBOURNE, Australia, and MENLO PARK, California U.S.A. (June 28, 2005): ChemGenex Pharmaceuticals Limited...
June 28, 2005
ChemGenex and Stragen Pharma Create Alliance to Accelerate Clinical Development and Commercialization of Ceflatonin®
MELBOURNE, Australia, and MENLO PARK, California U.S.A. and GENEVA, Switzerland (June 28, 2005): ChemGenex...
June 27, 2005
ChemGenex To List On NASDAQ (NASDAQ SC; CXSP)
MELBOURNE, Australia, and MENLO PARK, California U.S.A. (June 27, 2005): ChemGenex Pharmaceuticals Limited...
April 29, 2005
Monteray Group announces acquisition of GPen Pty Ltd
Listed investment company, Monteray Group Limited (ASX: MRY), today announced plans to acquire 100 per...
April 7, 2005
ChemGenex Launches Multi-Centre Phase 2 Clinical Trial of Ceflatonin® in Combination with Gleevec® in Patients with Chronic Myelogenous Leukemia
MELBOURNE, Australia, and MENLO PARK, California U.S.A. (April 7, 2005): ChemGenex Pharmaceuticals Limited...
March 22, 2005
Metal Storm ‘On Target' with Live Fire Demonstrations in US
BRISBANE, AUSTRALIA – 22 March 2005 – Metal Storm Limited (ASX trading code: MST and NASDAQ Small Cap...
March 2, 2005
Global investment delivers Charter Pacific $1 million dividend
Charter Pacific Corporation (ASX: CHF) today announced that it will receive approximately A$1 million...
March 1, 2005
CHEMGENEX PHARMACEUTICALS TAKES NEXT STEP IN NASDAQ LISTING PROCESS
ChemGenex Pharmaceuticals lodges a Form 20-F Registration Statement with the Securities and Exchange...
February 28, 2005
STRONG FIRST HALF BY CHARTER PACIFIC
Charter Pacific Corporation (ASX: CHF) today announced that it had delivered an underlying pre-tax profit...
February 23, 2005
CHEMGENEX TO PRESENT AT THE BIO CEO & INVESTOR CONFERENCE 2005
MELBOURNE, Australia, and MENLO PARK, California U.S.A. (February 23, 2005): ChemGenex Pharmaceuticals...
February 23, 2005
CHEMGENEX TO RECEIVE SIGNIFICANT MILESTONE PAYMENT FROM VERNALIS
MELBOURNE, Australia, and MENLO PARK, California U.S.A. (February 23, 2004): ChemGenex Pharmaceuticals...
February 17, 2005
CHEMGENEX PHARMACEUTICALS RECEIVES EUROPEAN ALLOWANCE FOR CANCER DRUG PATENT
ChemGenex Pharmaceuticals has received notice of allowance for a European patent covering the use of...
February 9, 2005
Chemgenex Licenses Targeted Platinum (IV) Compound from the University of Texas M.D. Anderson Cancer Center
New molecule is active in cancer cells that are resistant to existing platinum (II) agents MELBOURNE,...
February 8, 2005
Metal Storm Announces CEO Appointment and Board Changes
BRISBANE, AUSTRALIA - 8 February 2005 - Metal Storm Limited (ASX Trading Code: MST and NASDQ Small Cap...
February 8, 2005
CHEMGENEX PRESENTS POSITIVE CLINICAL TRIAL DATA ON ANTICANCER COMPOUND QUINAMED® AT U.S. CANCER CONFERENCE
MELBOURNE, Australia, and MENLO PARK, California U.S.A. (February 8, 2005): ChemGenex Pharmaceuticals...
January 31, 2005
Metal Storm Revises Handgun Development Timetables
BRISBANE, AUSTRALIA - 31 January 2005 – Metal Storm Limited (ASX trading code: MST and NASDAQ Small...
January 24, 2005
CHEMGENEX RAISES US$6.2 MILLION (A$8.2 MILLION) IN INTERNATIONAL PLACEMENT
MELBOURNE, Australia, and MENLO PARK, California U.S.A. (January 24, 2005): ChemGenex Pharmaceuticals...
January 5, 2005
METAL STORM CORRECTION
BRISBANE, AUSTRALIA - 5 January 2005 – Metal Storm Limited (ASX trading code: MST and NASDAQ Small Cap...